JP2016530495A5 - - Google Patents

Download PDF

Info

Publication number
JP2016530495A5
JP2016530495A5 JP2016522572A JP2016522572A JP2016530495A5 JP 2016530495 A5 JP2016530495 A5 JP 2016530495A5 JP 2016522572 A JP2016522572 A JP 2016522572A JP 2016522572 A JP2016522572 A JP 2016522572A JP 2016530495 A5 JP2016530495 A5 JP 2016530495A5
Authority
JP
Japan
Prior art keywords
antibody
drug
il6r
individual
tracer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016522572A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016530495A (ja
JP6563910B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/063891 external-priority patent/WO2015000865A1/en
Publication of JP2016530495A publication Critical patent/JP2016530495A/ja
Publication of JP2016530495A5 publication Critical patent/JP2016530495A5/ja
Application granted granted Critical
Publication of JP6563910B2 publication Critical patent/JP6563910B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016522572A 2013-07-04 2014-07-01 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ Active JP6563910B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13175091.1 2013-07-04
EP13175091 2013-07-04
PCT/EP2014/063891 WO2015000865A1 (en) 2013-07-04 2014-07-01 Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019137030A Division JP6761085B2 (ja) 2013-07-04 2019-07-25 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ

Publications (3)

Publication Number Publication Date
JP2016530495A JP2016530495A (ja) 2016-09-29
JP2016530495A5 true JP2016530495A5 (enExample) 2017-06-08
JP6563910B2 JP6563910B2 (ja) 2019-08-21

Family

ID=48703341

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016522572A Active JP6563910B2 (ja) 2013-07-04 2014-07-01 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ
JP2019137030A Active JP6761085B2 (ja) 2013-07-04 2019-07-25 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019137030A Active JP6761085B2 (ja) 2013-07-04 2019-07-25 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ

Country Status (10)

Country Link
US (2) US10168326B2 (enExample)
EP (1) EP3017303B1 (enExample)
JP (2) JP6563910B2 (enExample)
KR (1) KR102248581B1 (enExample)
CN (1) CN105378480B (enExample)
BR (1) BR112015032960B1 (enExample)
CA (1) CA2913687C (enExample)
MX (1) MX363403B (enExample)
RU (1) RU2674996C2 (enExample)
WO (1) WO2015000865A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN104928336B (zh) 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
EP2787007A3 (en) 2010-11-08 2015-03-11 F. Hoffmann-La Roche AG Subcutaneously administered ANTI-IL-6 receptor antibody
MX374652B (es) * 2014-02-11 2025-03-06 Genzyme Corp Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
WO2017102786A1 (en) 2015-12-16 2017-06-22 F. Hoffmann-La Roche Ag Three-step acid dissociation enzyme linked immunosorbent (tadelis) assay
EP3592367B1 (en) * 2017-03-07 2025-04-23 Roche Diagnostics GmbH Stable formulations for immune-modulatory macrolides
WO2019030202A1 (en) * 2017-08-08 2019-02-14 F. Hoffmann-La Roche Ag METHOD FOR DETECTION OF ANTI-MEDICATION ANTIBODIES IN A MINI-PORK SAMPLE
MX2020004921A (es) 2017-11-29 2020-08-27 Hoffmann La Roche Ensayo de anticuerpo antifarmaco con supresion de interferencia del objetivo.
US12055551B2 (en) 2018-07-10 2024-08-06 Regeneron Pharmaceuticals, Inc. Methods for mitigating drug target interference in an anti-drug antibody (ADA) immunoassay
EP3969907B1 (en) * 2019-05-13 2025-09-24 F. Hoffmann-La Roche AG Interference-suppressed pharmacokinetic immunoassay
EP4085251B1 (en) * 2020-01-02 2024-07-31 F. Hoffmann-La Roche AG Method for determining the amount of a therapeutic antibody in the brain
CN113495141A (zh) * 2020-03-20 2021-10-12 迈克生物股份有限公司 2019新型冠状病毒IgM抗体检测试剂盒
US20230167182A1 (en) * 2020-05-18 2023-06-01 Biosion Inc. Antibodies binding il6r and uses thereof
KR102626197B1 (ko) * 2020-11-19 2024-01-18 바디텍메드(주) 항 약물 항체의 수준을 정확하게 정량화하는 방법
JP7062803B1 (ja) 2021-03-31 2022-05-06 積水メディカル株式会社 抗薬物抗体測定方法
CN114047343B (zh) * 2022-01-13 2022-05-31 美迪西普亚医药科技(上海)有限公司 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用
IL322001A (en) * 2023-02-07 2025-09-01 Hoffmann La Roche Method for detecting antibodies to anti-AAV particles
EP4698909A1 (en) * 2023-04-20 2026-02-25 Xentria, Inc. Methods for detecting an anti-drug antibody (ada) against an anti-tnf alpha antibody
CN120761634B (zh) * 2025-09-02 2025-12-05 宁波熙宁检测技术有限公司 一种针对多特异性单克隆抗体药物的ada检测方法

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
JPH066054B2 (ja) 1987-10-15 1994-01-26 帝人株式会社 動物細胞の培養方法
US6428979B1 (en) 1988-01-22 2002-08-06 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
CA1341152C (en) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
US5068088A (en) 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
ZA898290B (en) 1988-11-03 1991-06-26 Igen Inc Electrochemiluminescent assays
KR0132666B1 (en) 1989-03-14 1998-04-14 Hitachi Kk Method for controlling cultivation conditions for animal cells
ATE144713T1 (de) 1989-07-20 1996-11-15 Tadamitsu Kishimoto Antikörper gegen menschlichen interleukin-6- rezeptor
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
IL100866A (en) 1991-02-06 1995-10-31 Igen Inc Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
US5821121A (en) 1991-06-24 1998-10-13 Pacific Biomedical Research, Inc. Hormone-secreting cells maintained in long-term culture
WO1993022448A1 (en) 1992-05-01 1993-11-11 Teijin Limited Fed batch culture method for protein secreting cells
EP0567738A3 (en) 1992-05-01 1995-09-06 American Cyanamid Co Controlling perfusion rates in continuous bioreactor culture of animal cells
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
JPH07258252A (ja) 1994-03-16 1995-10-09 Meiji Seika Kaisha Ltd チアゾール化合物およびその塩
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
JP3630453B2 (ja) 1994-09-30 2005-03-16 中外製薬株式会社 Il−6レセプター抗体を有効成分とする未熟型骨髄腫細胞治療剤
PL182089B1 (en) 1994-10-21 2001-11-30 Chugai Pharmaceutical Co Ltd Pharmaceutic compositions for treating diseases caused by production of il-6
AU704723B2 (en) 1994-12-29 1999-04-29 Chugai Seiyaku Kabushiki Kaisha Antitumor agent effect enhancer containing IL-6 antagonist
DK0811384T3 (da) 1995-02-13 2006-10-09 Chugai Pharmaceutical Co Ltd Muskelproteinnedbrydningsinhibitor indeholdende IL-6-receptor-antistof
US5614191A (en) 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
DE69638050D1 (de) 1995-10-23 2009-11-19 Zenyth Operations Pty Ltd Hemopoietin-rezeptor und dafür kodierende genetische sequenzen
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
PT923941E (pt) 1996-06-27 2006-09-29 Chugai Pharmaceutical Co Ltd Medicamentos para mieloma a serem utilizados com agentes antitumorais de mostarda nitrogenada
WO1998041611A1 (en) 1997-03-20 1998-09-24 Regents Of The University Of Minnesota Process for the continuous culture of cells
ES2312184T3 (es) 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
PT1074268E (pt) 1998-03-17 2008-02-28 Chugai Pharmaceutical Co Ltd Agentes profilácticos ou terapêuticos para doenças intestinais inflamatórias contendo anticorpos antagonistas do receptor il-6
US6537782B1 (en) 1998-06-01 2003-03-25 Chugai Seiyaku Kabushiki Kaisha Media for culturing animal cells and process for producing protein by using the same
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
ES2276525T3 (es) 1998-08-24 2007-06-16 Chugai Seiyaku Kabushiki Kaisha Preventivos o remedios para la pancreatitis que contienen anticuerpos anti-receptor il-6 como ingrediente activo.
US6284453B1 (en) 1999-09-29 2001-09-04 Steven Anthony Siano Method for controlling fermentation growth and metabolism
EP1298217A4 (en) 2000-07-05 2004-09-08 Mitsubishi Pharma Corp Process for the production of a glycoprotein
JP4812228B2 (ja) 2000-08-10 2011-11-09 中外製薬株式会社 抗体含有溶液の凝集物生成または白濁抑制方法
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
PT1356073E (pt) 2000-10-20 2010-02-15 Bioneer As Método de fermentação aperfeiçoado para a produção de produtos genéticos heterólogos em bactérias do ácido láctico
JP4261907B2 (ja) 2000-10-20 2009-05-13 中外製薬株式会社 低分子化アゴニスト抗体
WO2002034292A1 (fr) 2000-10-25 2002-05-02 Chugai Seiyaku Kabushiki Kaisha Agents preventifs ou therapeutiques contre le psoriasis renfermant l'antagoniste de l'il-6 comme substance active
WO2002036165A1 (fr) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
WO2002036164A1 (en) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
EP3088412B1 (en) 2001-03-09 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Protein purification method
WO2002076578A1 (en) 2001-03-27 2002-10-03 Smithkline Beecham Corporation Control of glycoforms in igg
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
WO2002101019A2 (en) 2001-06-13 2002-12-19 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
JP4432031B2 (ja) 2002-03-22 2010-03-17 ズィナイス オペレーションズ ピーティーワイ.エルティーディー. インターロイキン13受容体α1(IL−13Rα1)に対するモノクローナル抗体
JP3822137B2 (ja) 2002-05-20 2006-09-13 中外製薬株式会社 動物細胞培養用培地の添加剤およびそれを用いたタンパク質の製造方法
ES2626268T3 (es) 2002-09-11 2017-07-24 Chugai Seiyaku Kabushiki Kaisha Método de purificación de proteínas
AU2003291254A1 (en) 2002-11-05 2004-06-07 Mount Sinai School Of Medicine Of New York University ; Ptpn11 (shp-2) mutations and cancer
DE10255508A1 (de) 2002-11-27 2004-06-17 Forschungszentrum Jülich GmbH Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen
CA2516945A1 (en) 2003-02-24 2004-09-02 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for spinal cord injury comprising interleukin-6 antagonist
JPWO2004096274A1 (ja) 2003-03-31 2006-07-13 協和醗酵工業株式会社 気道内投与剤
ES2383014T3 (es) 2003-04-02 2012-06-15 F. Hoffmann-La Roche Ag Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US7429491B2 (en) 2003-05-15 2008-09-30 Wyeth Restricted glucose feed for animal cell culture
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
RU2554942C2 (ru) 2003-10-17 2015-07-10 Тугаи Сейяку Кабусики Кайся Терапевтический агент для мезотелиомы
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
WO2005090405A1 (ja) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha インターロイキン-6受容体に対するヒト型化抗体のサブタイプ
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
JP4818936B2 (ja) 2005-01-05 2011-11-16 中外製薬株式会社 細胞の培養方法およびその利用
AU2006300234B2 (en) 2005-10-14 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (ja) 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
EP3135298B1 (en) 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
CN101371140B (zh) 2006-03-09 2013-11-13 弗·哈夫曼-拉罗切有限公司 抗药物抗体的测定
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
WO2008016134A1 (fr) 2006-08-04 2008-02-07 Norihiro Nishimoto PROCÉDÉ POUR PRÉDIRE LE PRONOSTIC DES PATIENTS ATTEINTS DE POLYARTHRITE rhumatoïde
TWI434855B (zh) 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
JP2010095445A (ja) 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Il−6アンタゴニストを有効成分とする炎症性筋疾患治療剤
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
EP3246045B1 (en) 2007-07-26 2025-09-03 Osaka University Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
CN101939425B (zh) 2007-09-26 2014-05-14 中外制药株式会社 抗il-6受体抗体
AU2008308163B2 (en) 2007-10-02 2013-03-21 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient
BRPI0818674B1 (pt) 2007-10-15 2023-01-17 Chugai Seiyaku Kabushiki Kaisha Métodos para produção de um anticorpo inteiro ou de um fragmento do mesmo e para preparação de fármacos, bem como vetor recombinante
US8227195B2 (en) * 2007-12-15 2012-07-24 Hoffman-La Roche Inc. Distinguishing assay
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
DE102008005523A1 (de) 2008-01-23 2009-07-30 Robert Bosch Gmbh Kraftstoffinjektor
EP2271669A1 (en) 2008-03-11 2011-01-12 Genentech, Inc. Antibodies with enhanced adcc function
DE102008013899A1 (de) 2008-03-12 2009-09-17 F. Hoffmann-La Roche Ag Verfahren zur Herstellung rekombinanter Proteine bei konstantem Gehalt von pCO2 im Medium
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
TW201600110A (zh) 2009-07-31 2016-01-01 Shin Maeda 癌之轉移抑制劑
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
CN104928336B (zh) 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
WO2011128096A1 (en) 2010-04-16 2011-10-20 Roche Diagnostics Gmbh Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
EP2578233B1 (en) 2010-05-28 2017-04-26 National Cancer Center Therapeutic agent for pancreatic cancer
CA2801107A1 (en) 2010-06-07 2011-12-15 F. Hoffman-La Roche Ag Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
EP2787007A3 (en) * 2010-11-08 2015-03-11 F. Hoffmann-La Roche AG Subcutaneously administered ANTI-IL-6 receptor antibody
KR101993488B1 (ko) 2011-09-01 2019-06-26 추가이 세이야쿠 가부시키가이샤 한외여과에 의해 고도로 농축된 항체를 포함하는 조성물의 제조 방법

Similar Documents

Publication Publication Date Title
RU2016101730A (ru) Иммуноферментный анализ с подавлением интерференции для определения антител к лекарствам в образцах сыворотки
Robak et al. The role of Bruton’s kinase inhibitors in chronic lymphocytic leukemia: current status and future directions
Quiros-Roldan et al. The impact of immune system aging on infectious diseases
Lee et al. Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: a randomized controlled trial
Kotsiou et al. Calprotectin in lung diseases
Iriart et al. Pneumocystis pneumonia in solid-organ transplant recipients
Nista et al. Autoimmune pancreatitis: from pathogenesis to treatment
Benfaremo et al. Systemic sclerosis: from pathophysiology to novel therapeutic approaches
JP2017538671A5 (enExample)
Amelio et al. Mixed Th1 and Th2 Mycobacterium tuberculosis-specific CD4 T cell responses in patients with active pulmonary tuberculosis from Tanzania
JP2015530971A5 (enExample)
JP2010539162A5 (enExample)
JP2014530226A5 (enExample)
JP2018052979A5 (enExample)
Galateanu et al. Allergy in cancer care: antineoplastic therapy-induced hypersensitivity reactions
JP2016169229A5 (enExample)
MX2016005686A (es) Ensayo de union competitiva al ligando para detectar anticuerpos neutralizantes.
JP2016539925A5 (enExample)
Bąchor et al. Selected β2-, β3-and β2, 3-amino acid heterocyclic derivatives and their biological perspective
CN106381288A (zh) 一种抗h3n2亚型犬流感病毒核蛋白单克隆抗体杂交瘤2d10及单克隆抗体
Raacke et al. Altered Cytokine Response of Human Brain Endothelial Cells after Stimulation with Malaria Patient Plasma
Jasińska-Stroschein et al. Searching for Old and New Small-Molecule Protein Kinase Inhibitors as Effective Treatments in Pulmonary Hypertension—A Systematic Review
JP2017538786A5 (enExample)
Passariello et al. A novel human neutralizing mAb recognizes delta, gamma and omicron variants of SARS-CoV-2 and can be used in combination with sotrovimab
Kozireva et al. Upregulation of the Chemokine Receptor CCR2B in Epstein‒Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program